BiotechTube
Bryn Pharma

Bryn Pharma

Raleigh, United States· Est.
brynpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

Bryn Pharma is a clinical-stage biotech developing UTULY™, an intranasal spray formulation of epinephrine for anaphylaxis. The company aims to disrupt the established auto-injector market (e.g., EpiPen) by offering a needle-free, compact, and easy-to-administer option that could improve patient compliance and portability. Having completed a successful Phase 3 trial, Bryn is preparing for a New Drug Application (NDA) submission to the FDA. Its success hinges on regulatory approval, market adoption against entrenched competitors, and demonstrating clear advantages in usability and pharmacokinetics.

Allergy & Immunology

Technology Platform

Proprietary intranasal delivery system for systemic administration of epinephrine, designed to achieve rapid pharmacokinetic profiles comparable to intramuscular injection.

Funding History

1
Total raised:$50M
Series A$50M

Opportunities

The primary opportunity is to disrupt the multi-billion-dollar epinephrine auto-injector market by offering a needle-free, more portable, and user-friendly alternative.
This could significantly improve carriage and usage rates among patients with life-threatening allergies.
Successful approval could also position the intranasal platform for delivering other emergency therapeutics.

Risk Factors

Key risks include regulatory rejection or delays for its NDA, failure to gain market share against entrenched and well-funded competitors with established brand loyalty, and challenges in securing favorable insurance reimbursement.
As a small, pre-revenue company, it also faces significant financial and execution risks in launching a commercial product.

Competitive Landscape

Bryn Pharma competes directly with dominant epinephrine auto-injectors like Viatris's EpiPen and Kaleo's Auvi-Q, as well as generics. It also faces potential future competition from other companies developing alternative delivery methods (e.g., sublingual films, other nasal sprays). Its value proposition is differentiation on route of administration and form factor, not the drug molecule itself.

More companies in Drug Delivery & Formulation →More companies in United States →